Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News SAB Biotherapeutics Inc SABS

Healthcare Biotechnology
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SABS)

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

GlobeNewswire 11 days ago

SAB Biotherapeutics Provides SAB-142 Trial Update

GlobeNewswire April 16, 2024

SAB Biotherapeutics to Present at INNODIA Annual Meeting

GlobeNewswire April 8, 2024

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

GlobeNewswire April 4, 2024

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

GlobeNewswire March 29, 2024

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

GlobeNewswire March 25, 2024

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

GlobeNewswire February 23, 2024

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 8, 2024

SAB Biotherapeutics Announces Executive Leadership Change

GlobeNewswire February 2, 2024
View More News ››

Opinion & Analysis (NDAQ:SABS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SABS)

Sheesh!

Where is everybody?  People should be discussing this one.  Technicals are lining up nicely.  Just waiting for my trigger...
dragshot - June 1, 2023

Everybody put this stock on your radar for tomorrow.

I being new to stockhouse and mostly an otc trader, I think its good to get these dead stock BBs rolling with posts. Uploaded with...
Pennystockformula - October 30, 2013
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp is a Canadian company engaged in the acquisition, exploration, and development of natural ...
View More »